APAC Diabetes Devices Market

APAC Diabetes Care Devices Market Size (2022 to 2027)

The size of the Diabetes Care Devices Market in the Asia Pacific was estimated at USD 2.95 Billion in 2022. It is expected to reach USD 4.22 billion by 2027, at a CAGR of 7.41% during the forecast period from 2022 to 2027.

Diabetes is a group of metabolic disorders, a chronic conditions which is associated with an abnormally high level of sugar (glucose) in the blood. Southeast Asia currently witnesses 78.3 million people affected with Diabetes, which is going to reach 140.2 million by 2040. The Western Pacific region witnesses 153.2 million people affected with diabetes, and this number is said to reach 214.8 million by 2040.

The Asia Pacific has the highest diabetes population, with the number increasing at quite an alarming rate. Due to this, there is a massive demand for diabetes care devices, primarily driving the market. Also, the increasing healthcare costs operate the market with increased revenues accumulated by the companies in this region.

But the market growth is constrained here due to the low medical literacy rate, leading to the fall in sales of devices.

This research report on the APAC diabetes devices market has been segmented and sub-segmented into the following categories:

By Type: 

• Glucose Monitoring Devices
  • Self-Blood Glucose Monitoring Devices
    • Glucose Meters
    • Test strips
    • Lancets
    • Hemoglobin A1C Testing Kits    
  • Continuous Glucose Monitoring Devices
• Insulin Delivery Systems
  • Insulin Syringes
  • Insulin Pens
  • Insulin Pumps
  • Jet Injectors
• Control Solutions

By Country: 

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Regionally, countries such as China, India, Japan, Korea, and Australia. China and India are the leading contributors in this region with a significant incidence of companies involved in manufacturing diabetes care devices, due to the highest prevalence of Diabetes population in their areas. China has the world’s largest community, with close to 1.4 billion people, followed by India, with around 1.2 billion people in 2014. According to the International Diabetes Federation, China had the most significant number of diabetic patients, with about 96.2 million diabetic patients followed by India, with around 66.8 million diabetic patients in 2014. It represents a majority of approximately 40-45% of the global diabetic population living in India and China, providing significant opportunities for the global diabetes care devices companies to invest in this region.

A few of the leading companies operating in the APAC diabetes devices market profiled in this report are Roche Diagnostics, Johnson & Johnson, Abbott Laboratories, Novo Nordisk, Ascensia, Tandem, and Terumo.